Background
Generally, the preferred route of vascular access in chronic kidney disease patients is an arteriovenous fistula (AVF) rather than grafts. However, approximately 7% of 300,000 Japanese hemodialysis (HD) patients continue to dialyze with grafts [1, 2]. In patients who have arteriovenous grafts (AVGs), complications such as thrombosis, hemorrhaging, and infection are common, resulting in lower graft patency [3, 4]. Therefore, in our hospital, to improve graft patency, cases requiring HD immediately after AVG surgery (vascular access occlusion) undergo placement of a tunneled permanent catheter (cuffed tunneled catheter) in the internal jugular vein at the time of AVG creation to eliminate preemptive interventions in grafts at risk for thrombosis, hematoma, and infection.
We performed a retrospective analysis of the placement of a tunneled permanent catheter as temporary vascular access in AVG creation for long-term patency.
Case presentation
Case 1
A 49-year-old man from Japan was diagnosed with end-stage renal disease (ESRD) due to IgA nephritis. Initially, a left wrist radial-cephalic AVF was created for HD. Soon after creation, the AVF was thrombotically occluded, and the patient required AVF reconstruction in the left forearm. However, the reconstructed AVF became occluded again, and we decided to perform brachial-basilic AVG in the right forearm (because of the narrow vascular diameter) with placement of a tunneled permanent catheter (because of the immediate initiation of HD). The implantation graft was an ePTFE-based heparin-coated graft (Propaten; W.L. Gore, Flagstaff, AZ, USA), and cannulation was performed 36 days after its creation. At this point, there was no evidence of thrombosis, edema or infection. The catheter was placed for 44 days with no evidence of thrombosis or catheter-related bacteremia (CRB). At present, 956 days after the operation, the patient is receiving HD stably with no vascular access problems.
Case 2
An 80-year-old woman from Japan was diagnosed with ESRD of unknown cause 11 years ago, and a radial-cephalic AVF in the left forearm was created for HD. She needed to maintain vein patency with repeated percutaneous venous angioplasty (PTA). Despite the continuation of regular PTAs (every 3 months), her inadequate HD blood flow due to severe stenosis did not improve, so an alternative route of vascular access was considered. We decided to create a brachial-basilic AVG in the right forearm (because of the narrow vascular diameter) with placement of a tunneled permanent catheter (because of the immediate initiation of dialysis). The implantation graft (Vectra; Thoratec Laboratories Corporation, Berkeley, CA, USA) was a polyurethane graft, and cannulation was performed 21 days after its creation. At this point, there was no evidence of thrombosis, edema, or infection. The catheter was placed for 28 days with no evidence of thrombosis or CRB. Thereafter, on postoperative day 139, we performed angiography with PTA, which revealed anastomotic stenosis in the right brachiocephalic vein. PTA using a Sterling balloon dilatation catheter (Boston Scientific, Marlborough, MA, USA) was thus performed and resulted in good dilation.
Case 3
A 37-year-old man from Japan was diagnosed with ESRD due to purpura nephritis 22 years ago, and an AVF was created for HD. After the patient received his kidney transplantation, the AVF was discarded and chronically thrombosed. When the patient experienced kidney graft loss due to recurrent purpura nephritis, HD needed to be restarted. He had received HD for 15 years via a right forearm radial-cephalic AVF. However, at 37 years of age, the patient had a sudden episode of bleeding from a duodenal ulcer, and severe anemia and hypotension caused AVF occlusion. We placed a brachial-basilic AVG at the same point in the right forearm (because of chronic occlusion and long-discarded AVF access in the left forearm). Usually, a history of AVF creation in the same arm results in prolonged edema, so we decided to perform AVG with placement of a tunneled permanent catheter. The implantation graft was an ePTFE graft (Advanta; Atrium, Hudson, NH, USA), and cannulation was performed 57 days after its creation with perigraft seroma, which resolved spontaneously. The catheter was placed for 58 days with no evidence of thrombosis or CRB. At present, 592 days after the operation, the patient is stably receiving dialysis with no vascular access problems.
Case 4
A 74-year-old woman from Japan was diagnosed with ESRD due to nephrosclerosis 11 years ago, and a radial-cephalic AVF in the left forearm was created for HD. She needed to maintain vein patency with regular PTAs (every 3 months). However, severe stenosis remained even after dilation with PTA, so we decided to create an AVG at the same point in the left forearm (because the patient requested, we use the same arm) with placement of a tunneled permanent catheter (because of the immediate initiation of dialysis). The implantation graft was an ePTFE graft (Advanta), and cannulation was performed 94 days after its creation. At this point, there was no evidence of thrombosis, edema, or infection. The catheter was placed for 105 days with no evidence of thrombosis or CRB. On postoperative day 79, we performed angiography with PTA, which revealed anastomotic stenosis in the left brachiocephalic vein. PTA using the Sterling balloon dilatation catheter was thus performed and resulted in good dilation.
Discussion and conclusions
We use a tunneled (cuffed) permanent catheter instead of a nontunneled (noncuffed) temporary catheter because nontunneled temporary catheters often require replacement due to CRB and thrombotic occlusion before the first cannulation. In contrast, with a tunneled permanent catheter, a polyester cuff positioned approximately 2 cm from the skin exit site allows tissue ingrowth (biofilm formation) to function as an anchor and prevent bacterial migration [5]. This feature is associated with a marked reduction in the risk of CRB [6–8]. In addition, a tunneled permanent catheter facilitates living with a catheter, such as dressing, cleaning, and showering, which may improve the patients’ quality of life. Once edema in the access arm had completely improved, the first cannulation and then catheter removal were performed.
Our search of the literature revealed few reported cases comparing the performance of a tunneled permanent catheter versus a nontunneled temporary catheter in HD patients [6, 9–12] (Table 1). While these clinical outcomes may be related to variations in several parameters, such as catheter type, inserted position, duration of use, and catheter management (hygiene or use of antibiotics), nontunneled temporary catheters have demonstrated significantly higher infection rates than tunneled permanent catheters.
Table 1. Characteristics of infections in tunneled permanent catheters versus nontunneled temporary catheters
Number of catheters inserted | Number of infection | Observation period | Infection rates per 1000 catheter-days | Infection relative risk | Reference | |
|---|---|---|---|---|---|---|
Tunneled permanent catheter | 37 | 6 | 36-month period | 2.9 | RR 3.7 (1.8-7.5), p<0.001 | Weijmer et al. [6] |
Nontunneled temporary catheter | 235 | 52 | 12.8 | |||
Tunneled permanent catheter | 36 | NA | 16-month period | NA | RR 1.4 (0.6-3.4), p=0.41 | Mendu et al. [9] |
Nontunneled temporary catheter | 91 | NA | NA | |||
Tunneled permanent catheter | 310 | 86 | 24-month period | 5.5 | - | Saad et al. [10] |
Tunneled permanent catheter | 182 | 28 | 16-month period | 5.8 | - | Rocklin et al. [11] |
Tunneled permanent catheter | 108 (Patients) | 92 | 12-month period | 4.6 | - | Lee et al. [12] |
NA not available
Our study included a total of four conventional HD patients who had vascular access occlusion and required HD immediately after AVG surgery. The reason why the number of samples is still small is that our procedure has only been started recently, and in the cases of thrombotic occlusion, we are trying to reconstruct AVF in the upstream native shunt vessel. However, as the number of cases of graft use gradually increases, our procedure (AVG with tunneled permanent catheter) will likely see increased use in the near future.
The original shunt vessels have often already developed following AVF upstream reconstruction in thrombotic occlusion cases; thus, HD can be resumed with high blood flow despite immediate puncture after operation. Furthermore, native shunt vessels result in fewer infections than grafts; thus, we did not include AVF reconstruction cases in this study.
On the other hand, the immediate-use ePTFE graft (Acuseal; W. L. Gore & Associates, Newark, DE, USA) seems to be widely used overseas [13, 14]. However, in Japan, the sales and use of Acuseal had just been approved in 2015, and thus, there are no long-term clinical reports describing its use. Therefore, those grafts were not included in this study either.
All AVG surgeries were performed under local and brachial plexus block anesthesia. We used loop forearm grafts that were anastomosed to the brachial artery and basilic vein. There were no selection criteria for graft types. The graft efficacy, first cannulation date, postoperative complications, and graft patency over 1-year follow-up were evaluated. The details of individual patients and outcomes are summarized in Table 2.
Table 2. Proportions of AVG patients with a tunneled permanent catheter and their postoperative course
No | Graft | Patient demography | Postoperative course | ||||||
|---|---|---|---|---|---|---|---|---|---|
Age | Sex | Cause of renal failure | Catheter | First cannulation | Catheter removal | Complications | Follow up | ||
1 | Propaten | 49 | M | IgA nephropathy | Bio-Flex Tesio | 36 days | 44 days | – | 956 days |
2 | Thoratec (Vectra) | 80 | F | Unknown | Split Stream | 21 days | 28 days | Stenosis (PTA) | 778 days |
3 | Advanta | 37 | M | Purpura nephritis | Split Stream | 57 days | 58 days | Seroma | 592 days |
4 | Advanta | 74 | F | Nephrosclerosis | Split Stream | 94 days | 105 days | Stenosis (PTA) | 564 days |
PTA percutaneous transluminal angioplasty
The implantation grafts were cannulated with 16-gauge needles at a mean of 52 days after their creation, provided that there was no evidence of thrombosis, edema, or infection. The time between graft implantation and first cannulation was longer in patients 3 and 4 than in the others. This might be explained by the fact that edema was prolonged due to prior AVF creation in the same arm. The catheter was placed for a mean of 58 days with no evidence of thrombosis or CRB. Postoperative complications after 1 year were seroma (n = 1) and stenosis requiring PTA (n = 2) (Table 2). The cumulative primary-assisted patency after 1 year was 100%. Figure 1 shows a representative case at catheter removal, with no edema in the access arm (a) and no catheter troubles (b).
Fig. 1 [Images not available. See PDF.]
Left forearm loop graft (a) and Split Stream catheter in the right internal jugular vein (b), both at catheter removal, with no complications
In conclusion, this study showed that while the duration between AVG creation and its first use on HD has been prolonged, graft patency has been good. Although additional cases are required to confirm the efficacy of this approach, this finding enables the dialysis community to consider the initiation of AVG use immediately in cases of vascular access occlusion.
Acknowledgements
The authors would like to thank Drs. Shun Watanabe, Masahiko Oguro, Daisuke Ikuma, Hiroki Mizuno, Rikako Hiramatsu, Keiichi Sumida, Masayuki Yamanouchi, Tatsuya Suwabe, and Naoki Sawa for their careful patient management at Toranomon Hospital Kajigaya in Kanagawa, Japan.
Authors’ contributions
MM designed and wrote the manuscript. YN and KT treated the patients. YU and YI supervised the vascular access program and corrected the manuscript. All authors read and approved the final manuscript.
Funding
No funding was obtained for this study.
Availability of data and materials
All data supporting our findings are contained within the manuscript.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Written informed consent was obtained from the patients to publish this case report and any accompanying images. A copy of the written consent form is available for review by the editor of this journal.
Competing interests
The authors declare that they have no competing interests.
Abbreviations
Arteriovenous fistula
Arteriovenous graft
Catheter-related bacteremia
End-stage renal disease
Hemodialysis
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
1. Masakane, I; Taniguchi, M; Nakai, S; Tsuchida, K; Wada, A; Ogata, S; Hasegawa, T; Hamano, T; Hanafusa, N; Hoshino, J et al. Annual dialysis data report 2016, JSDT renal data registry. Adv Ren Replace Ther; 2018; 4,
2. Masakane, I; Taniguchi, M; Nakai, S; Tsuchida, K; Goto, S; Wada, A; Ogata, S; Hasegawa, T; Hamano, T; Hanafusa, N et al. Annual Dialysis data report 2015, JSDT renal data registry. Adv Ren Replace Ther; 2018; 4,
3. Harish, A; Allon, M. Arteriovenous graft infection: a comparison of thigh and upper extremity grafts. Clin J Am Soc Nephrol; 2011; 6,
4. Woo, K; Lok, CE. New insights into dialysis vascular access: what is the optimal vascular access type and timing of access creation in CKD and dialysis patients?. Clin J Am Soc Nephrol; 2016; 11,
5. Gallieni, M; Brenna, I; Brunini, F; Mezzina, N; Pasho, S; Giordano, A. Dialysis central venous catheter types and performance. J Vasc Access; 2014; 15,
6. Weijmer, MC; Vervloet, MG; ter Wee, PM. Compared to tunnelled cuffed haemodialysis catheters, temporary untunnelled catheters are associated with more complications already within 2 weeks of use. Nephrol Dial Transplant; 2004; 19,
7. Klouche, K; Amigues, L; Deleuze, S; Beraud, JJ; Canaud, B. Complications, effects on dialysis dose, and survival of tunneled femoral dialysis catheters in acute renal failure. Am J Kidney Dis; 2007; 49,
8. Clark, EG; Barsuk, JH. Temporary hemodialysis catheters: recent advances. Kidney Int; 2014; 86,
9. Mendu, ML; May, MF; Kaze, AD; Graham, DA; Cui, S; Chen, ME; Shin, N; Aizer, AA; Waikar, SS. Non-tunneled versus tunneled dialysis catheters for acute kidney injury requiring renal replacement therapy: a prospective cohort study. BMC Nephrol; 2017; 18,
10. Saad, TF. Bacteremia associated with tunneled, cuffed hemodialysis catheters. Am J Kidney Dis; 1999; 34,
11. Rocklin, MA; Dwight, CA; Callen, LJ; Bispham, BZ; Spiegel, DM. Comparison of cuffed tunneled hemodialysis catheter survival. Am J Kidney Dis; 2001; 37,
12. Lee, T; Barker, J; Allon, M. Tunneled catheters in hemodialysis patients: reasons and subsequent outcomes. Am J Kidney Dis; 2005; 46,
13. Wagner, JK; Dillavou, E; Nag, U; Ali, AA; Truong, S; Chaer, R; Hager, E; Yuo, T; Makaroun, M; Avgerinos, ED. Immediate-access grafts provide comparable patency to standard grafts, with fewer reinterventions and catheter-related complications. J Vasc Surg; 2019; 69,
14. Wagner, JK; Truong, S; Chaer, R; Dillavou, E; Hager, E; Yuo, T; Makaroun, M; Avgerinos, ED. Current experience and midterm follow-up of immediate-access arteriovenous grafts. Ann Vasc Surg; 2018; 53, pp. 123-127. [DOI: https://dx.doi.org/10.1016/j.avsg.2018.04.036] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30012446][PubMedCentral: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394226]
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
Background
Generally, the preferred route of vascular access in chronic kidney disease patients is an arteriovenous fistula (AVF) rather than grafts. However, approximately 7% of 300,000 Japanese hemodialysis (HD) patients continue to dialyze with grafts. In patients who have arteriovenous grafts (AVGs), complications such as thrombosis, hemorrhaging, and infection are common, resulting in lower graft patency. Therefore, in our hospital, to improve graft patency, cases requiring HD immediately after AVG surgery (vascular access occlusion) undergo placement of a tunneled (cuffed) permanent catheter in the internal jugular vein at the time of AVG creation to eliminate preemptive interventions in grafts at risk for thrombosis, hematoma, and infection. We use a tunneled permanent catheter instead of a nontunneled (noncuffed) temporary catheter because nontunneled temporary catheters often require replacement due to catheter-related bacteremia and thrombotic occlusion before the first cannulation.
Case presentation
Here, we present four conventional HD patients who had vascular access occlusion and required HD immediately after AVG surgery. The patients underwent placement of a tunneled permanent catheter for temporary vascular access in AVG creation. Once edema in the access arm had completely improved, the first cannulation and then catheter removal were performed.
Conclusions
In conclusion, while the duration between AVG creation and its first use on HD has been prolonged, graft patency has been good. Although additional cases are required to confirm the efficacy of this approach, this finding enables the dialysis community to consider the initiation of AVG use immediately in cases of vascular access occlusion.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Nakamura, Yuki 1 ; Tanaka, Kiho 1 ; Ubara, Yoshifumi 2 ; Ishii, Yasuo 1 1 Toranomon Hospital, Department of Surgery, Nephrology Center, Tokyo, Japan (GRID:grid.410813.f) (ISNI:0000 0004 1764 6940)
2 Toranomon Hospital, Nephrology Center, Tokyo, Japan (GRID:grid.410813.f) (ISNI:0000 0004 1764 6940); Okinaka Memorial Institute for Medical Research, Tokyo, Japan (GRID:grid.410813.f) (ISNI:0000 0004 1764 6940)